An Open-Label Extension Study to Evaluate Safety and Tolerability of Multiple Subcutaneous Doses of LY2439821 in Japanese Patients with Rheumatoid Arthritis on Concomitant Methotrexate
Phase 1
- Conditions
- Rheumatoid Arthritis
- Registration Number
- JPRN-jRCT2080221280
- Lead Sponsor
- Eli Lilly Japan K.K.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Have received 7 injections of LY2439821 subcutaneously and completed the follow-up period (14 weeks) in Study I1F-JE-RHAL 30mg/80mg/180mg cohort. Have received 11 injections of LY2439821 subcutaneously and completed the follow-up period (14 weeks) in Study I1F-JE-RHAL 240/120mg cohort.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method